Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGELLAN: Magnesium and Bisphosphonates in Postmenopausal Osteoporosis
NCT05328154Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Jun 2022
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of magnesium carbonate in postmenopausal osteoporosis, sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: C-terminal telopeptides of type 1 bone collagen at 1 year. Started Jun 2022; status: completed.
02
Drugs
magnesium carbonate
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT05328154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05328154.